2002-04-30-Bain-The_limits_of_scale_8页_115kb

The Limits of Scale in Big Pharma

Core Content

The document explores the challenges and opportunities facing the pharmaceutical industry as it seeks to grow beyond its current scale limitations. It argues that the traditional, fully integrated business model of Big Pharma—characterized by strict functional boundaries—has become inefficient and unsustainable. The key to future success lies in restructuring around a few therapeutic franchises (TFs) to enhance R&D productivity, streamline drug commercialization, and better serve profitable customer segments.

Main Points

1. The Problem of Scale

• R&D Spending vs. Drug Output: Despite a fivefold increase in R&D spending, Big Pharma has not increased the number of new chemical entities (NCEs) launched annually.
• Operating Margins: Operating margins for Big Pharma have only risen by 1%, while sales have grown significantly.
• Growth Gap: The gap in profitability between the top five and smaller pharmaceutical companies has narrowed, indicating the limitations of the current model.

2. Narrow Focus Leads to Better Performance

• Performance Comparison: Companies with a narrow focus on a few therapeutic franchises outperform broad-based competitors. For example, firms like GSK, Pfizer, and Merck generate 80% of their revenue from top three TFs, while broader-based companies like Roche and Novartis only get 58%.
• Growth Rates: Narrowly focused firms report 1.7 times more revenue growth and market capitalization than broader-based ones.
• Blockbuster Origins: Blockbusters are more often the result of a focused approach rather than serendipity. 70% of blockbusters from 1970–2000 came from TFs where the company already had a presence.

3. Threats to the Traditional Model

• New Competitors: Biotech firms are using advanced technologies to develop drugs more efficiently and target specific genetic profiles.
• Pharmacogenomics: This field allows for more personalized medicine, which challenges the one-size-fits-all approach of Big Pharma.
• Consumer Behavior: Patients are becoming more informed and price-sensitive, often choosing generic drugs over brand-name ones.
• Market Complexity: The industry is becoming more fragmented, requiring a portfolio-based approach to product management.
• Lack of Strategic Rigor: Decisions on drug investment are often made without clear strategic oversight, leading to inefficiencies.

4. Proposed Restructuring Strategy

• Reorganize Around TFs: Create business units focused on specific therapeutic franchises, with their own P&L, sales forces, and clinical development teams.
• Separate R&D Functions: Split R&D into independent research and development arms, allowing for more agility and entrepreneurship.
• Portfolio Management: Establish a cross-functional team to oversee drug development and investment decisions across all therapeutic franchises.

5. Benefits of the New Model

• Higher R&D Productivity: Companies with focused TFs can expect to launch more drugs at a lower cost.
• Licensing Opportunities: TFs can license new compounds from outside, increasing the number of products and chances of success.
• Better Lifecycle Management: Focused units can plan for drug lifecycle strategies, such as transitioning to OTC or developing generic alternatives.
• New Revenue Streams: TFs can identify and develop related products, such as diagnostics or devices, to enhance profitability.

6. Case Studies and Recommendations

• GlaxoSmithKline (GSK): Has started reorganizing R&D into six centers of excellence, aiming for greater autonomy and entrepreneurship.
• AstraZeneca: Has created a centralized sales and marketing infrastructure to better manage product launches and TFs.
• Action Steps:
  • Assess how to restructure the discovery business into an independent operation.
  • Identify and reorganize key therapeutic franchises into integrated business units.
  • Establish a cross-functional senior committee to manage the company’s portfolio and investment decisions.

Key Information

• Big Pharma’s R&D Spending: The top 10 companies spend on average $2.2 billion annually on R&D, yet launch only 1.6 NCEs per year.
• Blockbuster Requirements: To achieve a 10% sales growth, Big Pharma needs to double its NCE output.
• Net Present Value (NPV): A company restructured around TFs could see NPV nearly five times higher than a conventional Big Pharma firm.
• Incremental Cash: This reorganization could generate between $2B and $3.5B in incremental cash over the life of a blockbuster drug.

Conclusion

The document concludes that the traditional model of Big Pharma is no longer viable. A differentiated, focused strategy centered around a few therapeutic franchises is essential for sustainable growth, increased R&D efficiency, and better market responsiveness. While the transition will involve significant organizational changes and short-term costs, the long-term benefits are substantial. Companies must act quickly to restructure and adapt to the evolving pharmaceutical landscape.